Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabriva Gains New CEO And Near-Market Antibiotic, Claims Leadership Role

Executive Summary

The acquisition of Zavante Therapeutics and its late-stage investigational intravenous antibiotic for use in multi-drug resistant pathogens has also led to C-suite change at Nabriva Therapeutics.

Advertisement

Related Content

Keeping Track: FDA Starts November With A Bang
Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
Key Drug Launches To Plan For In 2019
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal
Alarm As Novartis Exits Antibiotics Space

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel